Aliases & Classifications for Opioid Addiction

MalaCards integrated aliases for Opioid Addiction:

Name: Opioid Addiction 26
Opiate Addiction 26 74
Opiate Dependence 26
Opioid Dependence 26

External Ids:

UMLS 74 C0524662

Summaries for Opioid Addiction

Genetics Home Reference : 26 Opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. Opioids are a class of drugs that act in the nervous system to produce feelings of pleasure and pain relief. Some opioids are legally prescribed by healthcare providers to manage severe and chronic pain. Commonly prescribed opioids include oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. Some other opioids, such as heroin, are illegal drugs of abuse.

MalaCards based summary : Opioid Addiction, also known as opiate addiction, is related to heroin dependence and morphine dependence. An important gene associated with Opioid Addiction is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Cytokine Signaling in Immune system. The drugs Buprenorphine and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Related Diseases for Opioid Addiction

Diseases related to Opioid Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 heroin dependence 32.1 DRD2 OPRD1 OPRM1
2 morphine dependence 31.9 CCK OPRD1 OPRK1 OPRM1
3 opiate dependence 30.4 DRD2 OPRD1 OPRK1 OPRM1
4 tobacco addiction 30.1 COMT DRD2 OPRM1
5 pain agnosia 30.0 CCK OPRK1 OPRM1 PNOC
6 drug dependence 29.9 DRD2 OPRD1 OPRK1 OPRM1
7 cocaine dependence 29.9 DRD2 OPRD1 OPRK1 OPRM1
8 attention deficit-hyperactivity disorder 29.8 COMT DRD2 GRIN2A OPRM1
9 neonatal abstinence syndrome 29.7 COMT CYP2B6 OPRD1 OPRK1 OPRM1
10 panic disorder 29.7 CCK CCKAR CCKBR COMT
11 opioid abuse 29.5 CCK CCKAR DRD2 GRIN3B OPRM1
12 disease of mental health 29.3 CCK COMT DRD2 GRIN2A OPRM1
13 schizophrenia 29.1 CCK CCKAR COMT DRD2 GRIN2A GRIN3B
14 alcohol dependence 28.6 CCK COMT DRD2 GRIN2A OPRD1 OPRK1
15 opioid dependence 1 12.4
16 pain - chronic 10.4
17 psychotic disorder 10.4
18 schizophreniform disorder 10.2 COMT DRD2
19 depression 10.2
20 pedophilia 10.2
21 paralytic ileus 10.2 ABCB1 CCK
22 polysubstance abuse 10.2 COMT DRD2
23 gastroparesis 10.1 ABCB1 CCK DRD2
24 eating disorder 10.1 CCK COMT DRD2
25 sexual disorder 10.1
26 personality disorder 10.1
27 cocaine abuse 10.1
28 substance dependence 10.0 DRD2 OPRD1 OPRK1 OPRM1
29 pol iii-related leukodystrophies 10.0
30 human immunodeficiency virus infectious disease 10.0
31 tardive dyskinesia 10.0 COMT DRD2
32 conduct disorder 10.0
33 substance abuse 10.0
34 gastrointestinal system disease 10.0 CCK CCKAR CCKBR
35 ocular motor apraxia 9.9
36 smoking as a quantitative trait locus 3 9.9
37 alexithymia 9.9
38 dipsogenic diabetes insipidus 9.9
39 agnosia 9.9 CCK OPRK1 OPRM1 PNOC
40 spondylolisthesis 9.9
41 arthritis 9.9
42 mood disorder 9.9
43 specific developmental disorder 9.9 CCK COMT OPRM1 PNOC
44 autism 9.9
45 pulmonary disease, chronic obstructive 9.9
46 hepatitis c virus 9.9
47 intraocular pressure quantitative trait locus 9.9
48 hepatitis 9.9
49 withdrawal disorder 9.9
50 borderline personality disorder 9.9

Comorbidity relations with Opioid Addiction via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Major Depressive Disorder Osteoporosis

Graphical network of the top 20 diseases related to Opioid Addiction:



Diseases related to Opioid Addiction

Symptoms & Phenotypes for Opioid Addiction

GenomeRNAi Phenotypes related to Opioid Addiction according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CCKAR CYP2B6 DRD2 GRIN2D MAPK1 OPRD1

MGI Mouse Phenotypes related to Opioid Addiction:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
2 endocrine/exocrine gland MP:0005379 9.96 ABCB1 CCK CCKAR CCKBR COMT DRD2
3 homeostasis/metabolism MP:0005376 9.93 ABCB1 CCK CCKAR CCKBR COMT DRD2
4 digestive/alimentary MP:0005381 9.92 ABCB1 CCKAR CCKBR DRD2 MAPK1 MAPK3
5 integument MP:0010771 9.65 CCKBR DRD2 GRIN2A GRIN2D MAPK1 MAPK3
6 nervous system MP:0003631 9.44 ABCB1 CCK CCKAR CCKBR COMT DRD2

Drugs & Therapeutics for Opioid Addiction

Drugs for Opioid Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 644073 40400
2
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
3
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
4
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
5
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
8
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 38396-39-3, 2180-92-9 2474
9
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
10
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
11
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
12
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
13
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
14
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 89594 942
15
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
16
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
17
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-42-6 5284603
18
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
19
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
20
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
21
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
22
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
23
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
24
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
25
Codeine Approved, Illicit Phase 4 76-57-3 5284371
26
Cobicistat Approved Phase 4 1004316-88-4
27
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
28
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
29
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
30 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Analgesics, Opioid Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
36 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37
Heroin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5462328
38 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiviral Agents Phase 4,Phase 3,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 503)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
4 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
5 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
6 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
7 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
8 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
9 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
10 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
11 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
12 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
13 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
14 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
15 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
16 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
17 HIV, Buprenorphine, and the Criminal Justice System (STRIDE2) Completed NCT03583138 Phase 4 buprenorphine
18 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
19 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
20 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
21 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
22 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
23 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
24 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
25 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
26 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
27 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
28 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
29 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
30 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
31 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
32 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
33 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
34 Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
35 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
36 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
37 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
38 A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
39 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
40 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
41 Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
42 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
43 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Active, not recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
44 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
45 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
46 Liposomal Bupivacaine in Ambulatory Hand Surgery Enrolling by invitation NCT02933814 Phase 4 Liposomal Bupivicaine
47 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept Not yet recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
48 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
49 Gabapentin Regimens and Their Effects on Opioid Consumption Not yet recruiting NCT03334903 Phase 4 Gabapentin
50 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine

Search NIH Clinical Center for Opioid Addiction

Genetic Tests for Opioid Addiction

Anatomical Context for Opioid Addiction

MalaCards organs/tissues related to Opioid Addiction:

42
Brain, Testes, Liver, Skin, Bone, Cortex, Eye

Publications for Opioid Addiction

Articles related to Opioid Addiction:

(show top 50) (show all 525)
# Title Authors Year
1
Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. ( 30786212 )
2019
2
Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction. ( 29441714 )
2019
3
Treatment for Opioid Addiction Must Be Offered in General Hospitals: But How? ( 30652975 )
2019
4
MicroRNA-132 in the Adult Dentate Gyrus is Involved in Opioid Addiction Via Modifying the Differentiation of Neural Stem Cells. ( 30721395 )
2019
5
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. ( 30729416 )
2019
6
Opioid addiction: long-acting formulations for a long-term disorder. ( 30792006 )
2019
7
Genetic Variant in the CRH-binding Protein Gene (CRHBP) is Associated With Cessation of Cocaine Use in Methadone Maintenance Patients With Opioid Addiction. ( 30844877 )
2019
8
Estimation of the Number of People With Opioid Addiction in Germany. ( 30961791 )
2019
9
Strategies to Identify Patient Risks of Prescription Opioid Addiction When Initiating Opioids for Pain: A Systematic Review. ( 31050783 )
2019
10
Opioid Addiction. ( 31085190 )
2019
11
Historical Review: Opiate Addiction and Opioid Receptors. ( 30419763 )
2019
12
Opioid addiction and borderline personality disorder. ( 29283477 )
2018
13
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary. ( 28862903 )
2018
14
Home-based delivery of XR-NTX in youth with opioid addiction. ( 28867062 )
2018
15
Opioid Addiction in Pregnancy: Does Depression Negatively Impact Adherence With Prenatal Care? ( 29068826 )
2018
16
Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. ( 29210332 )
2018
17
Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue. ( 29220615 )
2018
18
Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. ( 29266577 )
2018
19
Opioid addiction, diversion, and abuse in chronic and cancer pain. ( 29465470 )
2018
20
Tackling an Epidemic: New and Emerging Opioid Addiction Treatments Offer Hope for Solutions to This Crisis. ( 29553937 )
2018
21
Medication development in opioid addiction: Meaningful clinical end points. ( 29593105 )
2018
22
Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. ( 29676241 )
2018
23
The Neurobiology of Opioid Addiction and the Potential for Prevention Strategies. ( 29710202 )
2018
24
Intolerance of uncertainty and conditioned place preference in opioid addiction. ( 29844956 )
2018
25
Curbing opioid addiction needs more than new drugs. ( 29921860 )
2018
26
Molecular Genetics and New Medication Strategies for Opioid Addiction. ( 30068261 )
2018
27
Craving Behavior from Opioid Addiction Controlled with Olanzapine in an Advanced Cancer Patient: A Case Report. ( 30070936 )
2018
28
A review of opioid addiction genetics. ( 30118972 )
2018
29
Diagnosing opioid addiction in people with chronic pain. ( 30242012 )
2018
30
A public health approach to opioid addiction in North America. ( 30277881 )
2018
31
A public health approach to opioid addiction in North America - Author's reply. ( 30277884 )
2018
32
In Memoriam-Honoring the Victims of Opioid Addiction. ( 30304411 )
2018
33
Training community-based treatment providers to implement contingency management for opioid addiction: Time to and frequency of adoption. ( 30352667 )
2018
34
Opioid addiction, opioid addiction treatment, and HIV infection. ( 30384332 )
2018
35
The Clinical Concept of Opioid Addiction Since 1877: Still Wanting After All These Years. ( 30386269 )
2018
36
Removal of microglial-specific MyD88 signaling alters dentate gyrus doublecortin and enhances opioid addiction-like behaviors. ( 30447281 )
2018
37
Pharmacotherapy for opioid addiction in community corrections. ( 30522370 )
2018
38
Addressing the Rural Opioid Addiction and Overdose Crisis Through Cross-Sector Collaboration: Little Falls, Minnesota. ( 30571298 )
2018
39
Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine. ( 30713510 )
2018
40
Oxytocin and opioid addiction revisited: old drug, new applications. ( 28378414 )
2018
41
Changing the Treatment Direction for Opiate Addiction: Dr. Dole's Research. ( 29227710 )
2018
42
Social Influences in Animal Models of Opiate Addiction. ( 30193710 )
2018
43
Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders. ( 30401353 )
2018
44
Death Ambivalence and Treatment Seeking: Suicidality in Opiate Addiction. ( 30598866 )
2018
45
A Surging Drug Epidemic: Time for Congress to Enact a Mandate on Insurance Companies and Rehabilitation Facilities for Opioid and Opiate Addiction. ( 30889332 )
2018
46
Buprenorphine implants in medical treatment of opioid addiction. ( 28571505 )
2017
47
Opioid addiction and misuse in adult and adolescent patients with cancer. ( 28580748 )
2017
48
Five sentence letter from 1980 helped create US opioid addiction crisis, study concludes. ( 28588040 )
2017
49
Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption. ( 28607934 )
2017
50
Battling the biology of opioid addiction. ( 28697181 )
2017

Variations for Opioid Addiction

Expression for Opioid Addiction

Search GEO for disease gene expression data for Opioid Addiction.

Pathways for Opioid Addiction

Pathways related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 CCK CCKAR CCKBR DRD2 GRIN2A GRIN2D
2
Show member pathways
13.23 GRIN2A GRIN2D MAPK1 MAPK3 OPRD1 OPRM1
3
Show member pathways
12.65 CCK CCKAR CCKBR DRD2 GRIN2A GRIN2D
4
Show member pathways
12.63 COMT DRD2 GRIN2A GRIN2D GRIN3B MAPK1
5
Show member pathways
12.24 CCK CCKBR MAPK1 MAPK3
6 12.17 DRD2 GRIN2A GRIN2D GRIN3B
7
Show member pathways
12.04 CCKAR CCKBR GRIN2A GRIN2D
8
Show member pathways
11.87 DRD2 GRIN2A GRIN2D MAPK1 MAPK3
9 11.84 MAPK1 MAPK3 OPRD1
10
Show member pathways
11.82 GRIN2A GRIN2D GRIN3B
11
Show member pathways
11.8 ABCB1 COMT CYP2B6
12 11.76 DRD2 GRIN2A GRIN2D GRIN3B MAPK1 MAPK3
13
Show member pathways
11.74 DRD2 GRIN2A GRIN2D GRIN3B
14 11.64 DRD2 MAPK1 MAPK3
15 11.49 GRIN2A GRIN2D MAPK1 MAPK3
16
Show member pathways
11.46 ABCB1 COMT CYP2B6
17 11.18 GRIN2A GRIN2D GRIN3B
18 10.96 GRIN2A GRIN2D
19 10.96 MAPK1 MAPK3
20 10.93 MAPK1 MAPK3
21 10.91 MAPK1 MAPK3
22 10.9 MAPK1 MAPK3
23 10.87 MAPK1 MAPK3
24 10.87 MAPK1 MAPK3
25 10.86 MAPK1 MAPK3
26 10.83 MAPK1 MAPK3
27 10.75 MAPK1 MAPK3
28 10.67 MAPK1 MAPK3
29 10.66 CCK CCKBR
30 10.62 MAPK1 MAPK3

GO Terms for Opioid Addiction

Cellular components related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.85 CCK COMT DRD2 MAPK1 OPRM1
2 dendrite GO:0030425 9.85 CCK COMT DRD2 OPRK1 OPRM1 PNOC
3 postsynaptic membrane GO:0045211 9.8 COMT GRIN2A GRIN2D GRIN3B OPRD1
4 integral component of postsynaptic membrane GO:0099055 9.65 DRD2 OPRK1 OPRM1
5 integral component of presynaptic membrane GO:0099056 9.62 DRD2 OPRD1 OPRK1 OPRM1
6 axon terminus GO:0043679 9.56 DRD2 OPRD1 OPRK1 PNOC
7 pseudopodium GO:0031143 9.52 MAPK1 MAPK3
8 plasma membrane GO:0005886 9.47 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
9 spine apparatus GO:0097444 9.43 OPRD1 OPRM1
10 perikaryon GO:0043204 9.35 CCK DRD2 MAPK1 OPRK1 OPRM1
11 NMDA selective glutamate receptor complex GO:0017146 9.33 GRIN2A GRIN2D GRIN3B
12 membrane GO:0016020 10.34 ABCB1 CCKAR CCKBR COMT CYP2B6 DRD2
13 integral component of membrane GO:0016021 10.28 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
14 integral component of plasma membrane GO:0005887 10.05 CCKAR DRD2 GRIN2A GRIN2D OPRD1 OPRK1

Biological processes related to Opioid Addiction according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.99 ABCB1 COMT DRD2 GRIN2A
2 chemical synaptic transmission GO:0007268 9.98 GRIN2A MAPK1 OPRK1 PNOC
3 response to lipopolysaccharide GO:0032496 9.91 COMT MAPK1 MAPK3 OPRM1
4 calcium ion transmembrane transport GO:0070588 9.88 GRIN2A GRIN3B OPRM1
5 response to toxic substance GO:0009636 9.86 DRD2 MAPK1 MAPK3
6 locomotory behavior GO:0007626 9.86 DRD2 OPRK1 OPRM1
7 response to ethanol GO:0045471 9.86 DRD2 GRIN2A OPRK1 OPRM1
8 axonogenesis GO:0007409 9.85 CCK CCKAR DRD2
9 response to estrogen GO:0043627 9.83 COMT MAPK1 OPRK1
10 neuropeptide signaling pathway GO:0007218 9.83 OPRD1 OPRK1 OPRM1 PNOC
11 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.81 OPRD1 OPRK1 OPRM1
12 visual learning GO:0008542 9.79 CCK DRD2 GRIN2A
13 long-term synaptic potentiation GO:0060291 9.79 GRIN2A GRIN2D MAPK1
14 response to cocaine GO:0042220 9.76 DRD2 OPRK1 OPRM1
15 response to morphine GO:0043278 9.74 DRD2 OPRK1 OPRM1
16 lung morphogenesis GO:0060425 9.71 MAPK1 MAPK3
17 behavioral response to cocaine GO:0048148 9.71 DRD2 OPRK1
18 excitatory postsynaptic potential GO:0060079 9.71 DRD2 GRIN2A GRIN2D OPRM1
19 face development GO:0060324 9.7 MAPK1 MAPK3
20 positive regulation of long-term synaptic potentiation GO:1900273 9.7 DRD2 GRIN2A
21 positive regulation of telomere capping GO:1904355 9.7 MAPK1 MAPK3
22 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
23 cellular response to dopamine GO:1903351 9.69 MAPK1 MAPK3
24 regulation of ossification GO:0030278 9.69 MAPK1 MAPK3
25 behavioral response to ethanol GO:0048149 9.67 DRD2 OPRM1
26 outer ear morphogenesis GO:0042473 9.67 MAPK1 MAPK3
27 regulation of stress-activated MAPK cascade GO:0032872 9.67 MAPK1 MAPK3
28 ionotropic glutamate receptor signaling pathway GO:0035235 9.67 GRIN2A GRIN2D GRIN3B
29 Bergmann glial cell differentiation GO:0060020 9.66 MAPK1 MAPK3
30 excitatory chemical synaptic transmission GO:0098976 9.66 GRIN2A GRIN2D
31 MAPK cascade GO:0000165 9.65 MAPK1 MAPK3
32 calcium ion transmembrane import into cytosol GO:0097553 9.65 GRIN2A GRIN2D
33 regulation of early endosome to late endosome transport GO:2000641 9.64 MAPK1 MAPK3
34 trachea formation GO:0060440 9.63 MAPK1 MAPK3
35 caveolin-mediated endocytosis GO:0072584 9.63 MAPK1 MAPK3
36 startle response GO:0001964 9.63 DRD2 GRIN2A GRIN2D
37 regulation of cellular pH GO:0030641 9.62 MAPK1 MAPK3
38 dopamine metabolic process GO:0042417 9.61 COMT DRD2 GRIN2A
39 regulation of Golgi inheritance GO:0090170 9.6 MAPK1 MAPK3
40 response to epidermal growth factor GO:0070849 9.59 MAPK1 MAPK3
41 cardiac neural crest cell development involved in heart development GO:0061308 9.58 MAPK1 MAPK3
42 eating behavior GO:0042755 9.56 CCK OPRD1 OPRK1 OPRM1
43 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.55 OPRK1 OPRM1
44 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.55 CCKAR CCKBR OPRD1 OPRK1 OPRM1
45 cholecystokinin signaling pathway GO:0038188 9.54 CCKAR CCKBR
46 sensory perception GO:0007600 9.54 OPRK1 OPRM1 PNOC
47 opioid receptor signaling pathway GO:0038003 9.5 OPRD1 OPRK1 OPRM1
48 sensory perception of pain GO:0019233 9.35 GRIN2A MAPK1 MAPK3 OPRK1 OPRM1
49 regulation of sensory perception of pain GO:0051930 9.17 CCK COMT GRIN2A GRIN2D OPRD1 OPRK1
50 signal transduction GO:0007165 10.16 CCK CCKAR CCKBR DRD2 MAPK1 OPRD1

Molecular functions related to Opioid Addiction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 CCKAR CCKBR DRD2 OPRD1 OPRK1 OPRM1
2 MAP kinase kinase activity GO:0004708 9.48 MAPK1 MAPK3
3 MAP kinase activity GO:0004707 9.46 MAPK1 MAPK3
4 NMDA glutamate receptor activity GO:0004972 9.43 GRIN2A GRIN2D
5 receptor serine/threonine kinase binding GO:0033612 9.4 OPRD1 OPRK1
6 neuropeptide binding GO:0042923 9.33 OPRD1 OPRK1 OPRM1
7 glutamate-gated calcium ion channel activity GO:0022849 9.32 GRIN2A GRIN2D
8 cholecystokinin receptor activity GO:0004951 9.26 CCKAR CCKBR
9 ionotropic glutamate receptor activity GO:0004970 9.13 GRIN2A GRIN2D GRIN3B
10 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Opioid Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....